Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups

(MedPage Today) — Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial.
The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations…

Source link : https://www.medpagetoday.com/meetingcoverage/ers/117682

Author :

Publish date : 2025-09-28 21:04:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups

‘They Are Over Their Skis’: What We Heard This Week

Staff photographed sleeping at ‘unsafe’ York eating disorder unit

Related Posts

Patient-Reported Skin Changes After GLP-1 Use Explored

Biomass Cooking Pollution Not Linked to Pneumonia in Infants

Automatic Doors May Raise Risk for Injury Among Older Adults

GLP-1 RAs Effective for Weight Loss in T1D and Obesity

Remibrutinib for CSU Shows Sustained Efficacy at 1 Year

Kissing may have evolved in an ape ancestor 21 million years ago

Patient-Reported Skin Changes After GLP-1 Use Explored

Biomass Cooking Pollution Not Linked to Pneumonia in Infants

Automatic Doors May Raise Risk for Injury Among Older Adults

GLP-1 RAs Effective for Weight Loss in T1D and Obesity

Remibrutinib for CSU Shows Sustained Efficacy at 1 Year

Kissing may have evolved in an ape ancestor 21 million years ago

Sesame Allergy Study Compares Oral Food Challenge Methods

What’s in the New Settlement Against OxyContin-Maker Purdue and the Sackler Family

Categories

Archives